1 are correct that gene expression profilinginpatientswithcancerofunknownprimary(CUP)canbeuseful and in some instances complements immunohistochemistry in determining the primary cancer site or tissue of origin in these patients. However, the case presented is probably not CUP, but illustrates well one of the limitations of gene expression profiling in patients with suspected CUP.
The patient described was a man with a nodule on the right lower eyelid that had been present for at least 9 months. Biopsy showed an adenocarcinoma, and multiple (18) immunohistochemical (IHC) stains were performed on the biopsy specimen, but they did not suggest a specific primary site. Additional clinical evaluation showed no evidence of a primary tumor site. The gene expression profiling assay (Tissue of Origin Test; Pathwork Diagnostics, Sunnyvale, CA) strongly supported breast cancer as the cell of origin. It is much more likely that this patient had a primary adnexal skin carcinoma (sweat gland or hair follicle) arising from his lower eyelid. Adnexal carcinomas can be easily mistaken for metastatic adenocarcinoma and occasionally show IHC staining that is very similar to that of breast cancers as well as salivary gland cancers.
2 Furthermore, consistent with similar protein synthesis, there seems to be some degree of overlap of the gene expression profiles of breast, adnexal skin, and salivary gland carcinomas. These tumor types share some common embryologic lineage and the morphology of these tumors at times can be nearly identical.
2 Whenonlyonesiteofneoplasmisidentifiedinapatientsuspectedof having CUP, the possibility of an unusual primary tumor mimicking metastatic disease should always be considered. 3 Skin adnexal carcinomas are rare neoplasms and are not included in the panel of tumors that are recognized by any of the three commercially available gene expression assays that are designed to determine the tissue of origin. The fact that the patientisamanwhopresentedwithasolitarylesiononhisrighteyelidand no other clinical evidence of metastatic disease would make an occult primary breast cancer with a metastasis to the eyelid exceedingly unlikely. However, the gene expression profile of an adnexal skin carcinoma would most likely list breast as a high probability. The gene expression assay reports often mention the possibility of cross reactivity in some clinical settings. It is possible that additional IHC staining with p63 and cytokeratin 5/6, if positive, would further substantiate the diagnosis of a skin adnexal carcinoma. 4 Most patients with adnexal skin tumors are best treated by excision, and their prognosis is considerably better than that of patients with metastatic carcinoma.
Regardless of the true tissue of origin of the tumor, the points made by the authors regarding gene expression profiling in CUP were insightful and valid. Recently, the outcome or survival of patients with CUP has been improved by site-specific therapy directed by a molecular assay diagnosis compared with empiric chemotherapy regimens.
Gene expression profiling also has limitations. The assays are 85% to 90% accurate in predicting the primary tumor site, as confirmed by studies with known primary cancers, and this was referenced by the authors. Several different tumors may share, to some extent, gene expression profiles and may result in an incorrect diagnosis, not truly representing the tissue of origin of the neoplasm. The case presented by the authors most likely represents such an example. Gene expression profiling assays that are designed to determine the tissue of origin do not have every neoplasm necessary for comparison in their panels of known tumors. If a patient has a cancer that is not in the panel, there is a higher likelihood of an inaccurate diagnosis.
The entire clinicopathologic setting needs to be considered when interpreting the results of gene expression profiling diagnosis in patients with CUP. Clinical judgment remains an important element in the interpretation of molecular diagnostic testing.
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